Deflazacort
Deflazacort, Emflaza, Jaythari (deflazacort) is a small molecule pharmaceutical. Deflazacort was first approved as Emflaza on 2017-02-09. It is used to treat duchenne muscular dystrophy and inflammation in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Deflazacort, Emflaza, Jaythari, Pyquvi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deflazacort
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMFLAZA | PTC Therapeutics | N-208684 RX | 2017-02-09 | 4 products, RLD, RS |
| EMFLAZA | PTC Therapeutics | N-208685 RX | 2017-02-09 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| deflazacort | ANDA | 2025-05-06 |
| deflazacort oral suspension | ANDA | 2025-05-31 |
| emflaza | New Drug Application | 2024-06-18 |
| jaythari | ANDA | 2025-05-19 |
| pyquvi | ANDA | 2025-07-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| inflammation | MP_0001845 | D007249 | — |
| duchenne muscular dystrophy | EFO_0000429 | D020388 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEFLAZACORT, EMFLAZA, PTC THERAP | |||
| 2026-06-07 | ODE-252 | ||
| 2024-02-09 | ODE-130 | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | 2 | — | 2 | — | 1 | 5 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | 2 | — | 1 | — | 1 | 4 |
| Limb-girdle muscular dystrophies | D049288 | EFO_0000758 | G71.03 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deflazacort |
| INN | deflazacort |
| Description | Deflazacort is a corticosteroid hormone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C |
Identifiers
| PDB | — |
| CAS-ID | 14484-47-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201891 |
| ChEBI ID | — |
| PubChem CID | 189821 |
| DrugBank | DB11921 |
| UNII ID | KR5YZ6AE4B (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Emflaza – PTC Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,136 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,998 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use